Paola Patrignani

Articles in Scholarly Journals [Incomplete List]

  1. Pharmacodynamic of cyclooxygenase inhibitors in humans
    Prostaglandins & Other Lipid Mediators, vol. 82, no. 1-4, pp. 85–94, 2007
  2. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways
    The FASEB Journal, vol. 21, no. 10, pp. 2418–2430, 2007
  3. Human Pharmacology of Naproxen Sodium
    Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 453–460, 2007
  4. Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells
    Clinical Cancer Research, vol. 12, no. 3, pp. 735–741, 2006
  5. Renal artery stenosis and accelerated atherosclerosis: which comes first?
    Journal of Hypertension, vol. 24, no. 9, p. 1687???1696, 2006
  6. The ever growing story of cyclo-oxygenase inhibition
    The Lancet, vol. 368, no. 9549, pp. 1745–1747, 2006
  7. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease
    Clinical Pharmacology & Therapeutics, vol. 80, no. 2, pp. 115–125, 2006
  8. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
    Clinical Pharmacology & Therapeutics, vol. 80, no. 3, pp. 264–274, 2006
  9. De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin
    Circulation Research, vol. 98, no. 5, pp. 593–595, 2006
  10. Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo
    Blood, vol. 107, no. 9, pp. 3572–3574, 2006
  11. Clinical pharmacology of etoricoxib
    Expert Opinion on Drug Metabolism Toxicology, vol. 1, no. 2, pp. 269–282, 2005
  12. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
    Journal of the American College of Cardiology, vol. 45, no. 8, pp. 1295–1301, 2005
  13. Platelet activation in patients with colorectal cancer
    Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 72, no. 2, pp. 79–83, 2005
  14. New insights into COX-2 biology and inhibition
    Brain Research Reviews, vol. 48, no. 2, pp. 352–359, 2005
  15. Isoprostanes and other markers of peroxidation in atherosclerosis
    Biomarkers, vol. 10, no. 6, pp. 24–29, 2005
  16. Journal of Medicinal Chemistry, vol. 47, no. 20, pp. 4881–4890, 2004
  17. Expression of COX-2, mPGE-synthase1, MDR-1(P-gp), and Bcl-xL: a molecular pathway ofH pylori-related gastric carcinogenesis
    The Journal of Pathology, vol. 202, no. 3, pp. 305–312, 2004
  18. Lumiracoxib
    Drugs, vol. 64, no. 19, pp. 2247–2248, 2004
  19. Clinical Pharmacology of Novel Selective COX-2 Inhibitors
    Current Pharmaceutical Design, vol. 10, no. 6, pp. 589–601, 2004
  20. Preface [Hot topic: New Insights into COX-2 Biology and Inhibition (Executive Editor: Paola Patrignani)]
    Current Pharmaceutical Design, vol. 10, no. 6, pp. 1–1, 2004
  21. Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects
    Circulation, vol. 109, no. 12, pp. 1468–1471, 2004
  22. Determinants of Platelet Activation in Human Essential Hypertension
    Hypertension, vol. 43, no. 1, pp. 64–70, 2003
  23. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells
    British Journal of Pharmacology, vol. 138, no. 4, Article ID 0705078, 7 pages, 2003
  24. Cox2 and MDR-1 Pg-P expression in gastric mucosa: A molecular pathway of Helicobacter pylori related- gastric carcinogenesis
    Gastroenterology, vol. 124, no. 4, pp. A594–A594, 2003
  25. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease
    Thrombosis Research, vol. 110, no. 5-6, pp. 281–286, 2003
  26. Modulation of Aspirin-Insensitive Eicosanoid Biosynthesis by 6-Methylprednisolone in Unstable Angina
    Circulation, vol. 107, no. 1, pp. 55–61, 2003
  27. Isoprostanes: Are They More Than Physiopathological Biomarkers of Lipid Peroxidation? * Response
    Circulation, vol. 107, no. 24, pp. 222e–222, 2003
  28. Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease
    Circulation, vol. 106, no. 22, pp. 2800–2805, 2002
  29. Enhaced cortisol secretion does not control aspirin-insensitivess thromboxane biosynthesis in patients with acute coronary syndromes
    Journal of the American College of Cardiology, vol. 39, p. 334, 2002
  30. The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity
    Current Medical Research and Opinion, vol. 18, no. 8, pp. 503–511, 2002
  31. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs
    Journal of Clinical Investigation, vol. 108, no. 1, pp. 7–13, 2001
  32. The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids
    Clinical Pharmacology & Therapeutics, vol. 70, no. 5, pp. 475–483, 2001
  33. Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer
    Toxicology Letters, vol. 112-113, no. 1-3, pp. 493–498, 2000
  34. APOPTOSIS, vol. 4, no. 3, pp. 151–162, 1999
  35. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings
    Clinical Pharmacology & Therapeutics, vol. 63, no. 6, pp. 672–681, 1998
  36. Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases
    European Journal of Pharmacology, vol. 316, no. 1, pp. 65–72, 1996
  37. Effects of nabumetone on prostanoid biosynthesis in humans
    Clinical Pharmacology & Therapeutics, vol. 58, no. 3, pp. 335–341, 1995
  38. Eicosanoid Biosynthesis and Metabolism in Myeloproliferative Disorders
    Annals of the New York Academy of Sciences, vol. 744, no. 1 Cellular Gene, pp. 229–236, 1994
  39. Differential Effects of Leukotriene C4 on Endothelin-1 and Prostacyclin Release by Cultured Vascular Cells
    Pharmacological Research, vol. 27, no. 3, pp. 281–286, 1993
  40. Effects of various prostaglandin synthesis inhibitors on the tone of the lower oesophageal sphincter in man
    European Journal of Clinical Pharmacology, vol. 43, no. 3, pp. 303–305, 1992
  41. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole Mood
    European Journal of Pharmacology, vol. 191, no. 1, pp. 83–88, 1990
  42. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey
    Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 992, no. 1, pp. 71–77, 1989
  43. Biosynthesis, characterization and inhibition of leukotriene B4 in human whole blood
    Prostaglandins, vol. 33, no. 4, pp. 539–551, 1987
  44. Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferation
    Biochemical and Biophysical Research Communications, vol. 148, no. 2, pp. 802–810, 1987
  45. Pharmacologic modulation of arachidonic acid metabolism in man. A minireview with emphasis on radioimmunological methods used to quantitate drug effects
    International Journal of Immunopharmacology, vol. 4, no. 2, pp. 127–133, 1982